Skip to main content

Animations

MJFF Publications

431 - 440 of 6255 Results
Title
Year
  • Year
  • 2022
  • 2021
  • 2022
  • 2022
  • 2022
  • 2018
  • 2018
  • 2019
  • 2019
  • 2019
  • Summary Details
    OPEN
    Title: Multi-transcriptomic analysis points to early organelle dysfunction in human astrocytes in Alzheimer's disease
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105655
    Citation Count: 61
  • Summary Details
    OPEN
    Title: BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease
    Journal Name: Neuromodulation: Technology at the Neural Interface
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1111/ner.13504
    Citation Count: 9
  • Summary Details
    OPEN
    Title: Cytosolic sequestration of spatacsin by Protein Kinase A and 14-3-3 proteins
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105858
    Citation Count: 5
  • Summary Details
    OPEN
    Title: A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105612
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Special Issue on new therapeutic approaches to Parkinson disease
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.108998
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Genetic analysis of neurodegenerative diseases in a pathology cohort
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2018.11.007
    Best OA location URL:
    Citation Count: 38
  • Summary Details
    OPEN
    Title: Common and rare GCH1 variants are associated with Parkinson's disease
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2018.09.008
    Best OA location URL:
    Citation Count: 29
  • Summary Details
    OPEN
    Title: Miro1 Marks Parkinson’s Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinson’s Models
    Journal Name: Cell Metabolism
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.cmet.2019.08.023
    Citation Count: 139
  • Summary Details
    OPEN
    Title: Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures
    Journal Name: Clinical Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.prdoa.2019.08.006
    Citation Count: 30
  • Summary Details
    OPEN
    Title: Cognitive processes that indirectly affect olfactory dysfunction in Parkinson's disease
    Journal Name: Clinical Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.prdoa.2019.07.003
    Citation Count: 6
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.